Vor Biopharma (NYSE:VOR – Get Free Report)‘s stock had its “outperform” rating restated by research analysts at Wedbush in a research report issued to clients and investors on Thursday, RTT News reports. They presently have a $11.00 price target on the stock. Wedbush’s target price points to a potential upside of 485.11% from the stock’s previous close.
Other equities research analysts have also issued research reports about the company. JMP Securities reaffirmed a “market outperform” rating and issued a $12.00 price target on shares of Vor Biopharma in a research report on Monday, August 14th. HC Wainwright reissued a “buy” rating and issued a $17.50 target price on shares of Vor Biopharma in a report on Friday, August 11th. Finally, Stifel Nicolaus reduced their price objective on Vor Biopharma from $16.00 to $15.00 in a research report on Friday, August 11th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, Vor Biopharma currently has an average rating of “Buy” and a consensus price target of $15.19.
Vor Biopharma Price Performance
Vor Biopharma (NYSE:VOR – Get Free Report) last posted its quarterly earnings data on Thursday, August 10th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.03). Analysts anticipate that Vor Biopharma will post -1.82 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Vor Biopharma
A number of large investors have recently modified their holdings of VOR. Bank of Montreal Can bought a new position in Vor Biopharma during the 1st quarter worth approximately $283,000. Ergoteles LLC acquired a new stake in shares of Vor Biopharma in the first quarter worth $97,000. State Street Corp boosted its position in Vor Biopharma by 6.7% during the first quarter. State Street Corp now owns 283,076 shares of the company’s stock valued at $1,710,000 after purchasing an additional 17,891 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Vor Biopharma by 48.6% in the first quarter. Goldman Sachs Group Inc. now owns 25,607 shares of the company’s stock worth $155,000 after buying an additional 8,370 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in shares of Vor Biopharma in the second quarter worth about $86,000. Institutional investors and hedge funds own 90.01% of the company’s stock.
About Vor Biopharma
Vor Biopharma Inc, a clinical-stage company, engages in the development of engineered hematopoietic stem cell (eHSC) therapies for cancer patients. The company is developing lead product, tremtelectogene empogeditemcel (trem-cel), formerly VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies.
- Five stocks we like better than Vor Biopharma
- Stock Market Upgrades: What Are They?
- Shocking uranium play that hedge funds kept hidden
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Dependable dividends: Why utility stocks are on fire
- What is a Stock Market Index and How Do You Use Them?
- Realtor verdict, poor revenue guidance send Zillow stock plunging
Receive News & Ratings for Vor Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vor Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.